DK2788478T3 - Multiplex-immunscreeningsassay - Google Patents

Multiplex-immunscreeningsassay Download PDF

Info

Publication number
DK2788478T3
DK2788478T3 DK12798308.8T DK12798308T DK2788478T3 DK 2788478 T3 DK2788478 T3 DK 2788478T3 DK 12798308 T DK12798308 T DK 12798308T DK 2788478 T3 DK2788478 T3 DK 2788478T3
Authority
DK
Denmark
Prior art keywords
gly
ala
leu
val
pro
Prior art date
Application number
DK12798308.8T
Other languages
English (en)
Inventor
Jean-Claude Manuguerra
Jessica Vanhomwegen
Sylvie Paulous
Philippe Despres
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/072387 external-priority patent/WO2012076715A1/en
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK2788478T3 publication Critical patent/DK2788478T3/da

Links

Classifications

    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/01—Head-up displays
    • G02B27/017—Head mounted
    • G02B27/0172—Head mounted characterised by optical features
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/0081—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00 with means for altering, e.g. enlarging, the entrance or exit pupil
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/42—Diffraction optics, i.e. systems including a diffractive element being designed for providing a diffractive effect
    • G02B27/4272—Diffraction optics, i.e. systems including a diffractive element being designed for providing a diffractive effect having plural diffractive elements positioned sequentially along the optical path
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B5/00—Optical elements other than lenses
    • G02B5/18—Diffraction gratings
    • G02B5/1814—Diffraction gratings structurally combined with one or more further optical elements, e.g. lenses, mirrors, prisms or other diffraction gratings
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/0001—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems
    • G02B6/0011—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form
    • G02B6/0013—Means for improving the coupling-in of light from the light source into the light guide
    • G02B6/0015—Means for improving the coupling-in of light from the light source into the light guide provided on the surface of the light guide or in the bulk of it
    • G02B6/0016—Grooves, prisms, gratings, scattering particles or rough surfaces
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B6/00—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings
    • G02B6/0001—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems
    • G02B6/0011—Light guides; Structural details of arrangements comprising light guides and other optical elements, e.g. couplings specially adapted for lighting devices or systems the light guides being planar or of plate-like form
    • G02B6/0033—Means for improving the coupling-out of light from the light guide
    • G02B6/0035—Means for improving the coupling-out of light from the light guide provided on the surface of the light guide or in the bulk of it
    • G02B6/0038—Linear indentations or grooves, e.g. arc-shaped grooves or meandering grooves, extending over the full length or width of the light guide
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T19/00—Manipulating 3D models or images for computer graphics
    • G06T19/006—Mixed reality
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/01—Head-up displays
    • G02B27/0101—Head-up displays characterised by optical features
    • G02B2027/0123—Head-up displays characterised by optical features comprising devices increasing the field of view
    • G02B2027/0125—Field-of-view increase by wavefront division
    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
    • G02B27/01—Head-up displays
    • G02B27/017—Head mounted
    • G02B27/0172—Head mounted characterised by optical features
    • G02B2027/0174—Head mounted characterised by optical features holographic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Claims (12)

  1. I
    1. In Wfro-assay-fremgangsmåde til detektering af mindst to target-antistoffer i en biologisk prøve, omfattende: 5 (a) at bringe en første fast bærer omfattende et AGT-substrat, der er kovalent koblet til et første fusionsprotein omfattende et AGT-polypeptid, der har en 06-alkylguanin-DNA-alkyltransferaseaktivitet, og en første epitop, der genkendes af et første target-antistof, med den biologiske prøve, hvor AGT-substratet yderligere er kovalent koblet til den første faste bærer; D (b) at bringe en anden fast bærer omfattende et AGT-substrat, der er kova lent koblet til et andet fusionsprotein omfattende et AGT-polypeptid, der har en 06-alkylguanin-DNA-alkyltransferaseaktivitet, og en anden epitop, der genkendes af et andet target-antistof, men ikke af det første target-antistof, med den biologiske prøve, hvor AGT-substratet yderligere er kovalent koblet 5 til den anden faste bærer; og (c) at detektere forekomst eller fravær af de to target-antistoffer.
  2. 2. Assay-fremgangsmåde ifølge krav 1, hvor fremgangsmåden anvendes til at detektere mindst 5, mere fortrinsvis mindst 15 og endnu mere foretrukket D mindst 50 target-antistoffer i en biologisk prøve fra et individ.
  3. 3. Assay-fremgangsmåde ifølge et hvilket som helst af kravene 1 til 2, hvor substratet af AGT-polypeptidet er et 06-benzylguanin-derivat med formel I: 5 R1-X-CH2-R3-R4-Y hvori: - R1 er en heteroaromatisk gruppe indeholdende 1 til 5 nitrogenatomer, fortrinsvis et purin-radikal med formel: D R/ hvori R5 er hydrogen, halogen, f.eks. chlor eller brom, trifluormethyl eller hydroxy; R6 er hydrogen, hydroxy eller usubstitueret eller substitueret amino; og R2 er hydrogen, et alkyl af 1 til 10 carbonatomer eller en sacchariddel; £. - X er et oxygen- eller svovlatom; fortrinsvis et oxygenatom; - R3 er en aromatisk eller en heteroaromatisk gruppe eller en eventuelt substitueret umættet alkyl-, cycloalkyl- eller heterocyclylgruppe med dobbeltbindingen forbundet med CH2; fortrinsvis et phenyl, f.eks. et phenyl substitueret 5 med R4 i para- eller metaposition, - R4 er en linker-del, fortrinsvis -CH2-NH-C0-NH-[C2H4-0]n-, hvor n ligger mellem 1 til 8, fortrinsvis 2 til 6; - Y er en reaktiv gruppe.
  4. 4. Assay-fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, hvor de faste bærere kan identificeres specifikt ved deres specifikke lokation, størrelse, diameter, vægt, granulometri og/eller mærkning.
  5. 5. Assay-fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor 5 de faste bærere er mærket med et fluorkrom, en kromofor, en radioisotop og/eller en massemarkør.
  6. 6. Assay-fremgangsmåde ifølge et hvilket som helst af kravene 1 til 5, hvor de faste bærere er mikropartikler, fortrinsvis magnetiske mikropartikler eller D mikropartikler, der er mærket indvendigt med fluorescerende farvestoffer.
  7. 7. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 6, hvor de første og anden faste bærere opnås ved kovalent kobling af AGT-polypeptidet, der er indeholdt i fusionsproteinet som defineret i krav 1, til en første og en 5 anden funktionaliseret fast bærer, ved at udføre en fremgangsmåde, der om fatter trinnene: i) at aktivere hver af de funktionaliserede faste bærere, ii) at tilsætte et substrat af AGT-polypeptidet, hvilket substrat er suspenderet i en buffer indeholdende mellem 0 og 20 % af DMSO, under passende betin- D gelser, således at substratet bindes kovalent til bæreren, og iii) at bringe AGT-polypeptidet i kontakt med hver af de substratcoatede bærere fra trin b) i en PBS/DTT-buffer, idet DTT fortrinsvis er i en koncentration på 1 mM i PBS/DTT-bufferen, hvor ikke-bundne molekyler vaskes ud efter trin ii) og iii). 5 o
  8. 8. Anvendelse af et kit omfattende: (a) en første fast bærer omfattende et AGT-substrat, der er kovalent koblet til et første fusionsprotein omfattende et AGT-polypeptid, der har en 06-alkylguanin-DNA-alkyltransferaseaktivitet, og en første epitop, der genkendes 5 af et første target-antistof, hvor AGT-substratet yderligere er kovalent koblet til den første faste bærer; og (b) en anden fast bærer omfattende et AGT-substrat, der er kovalent koblet til et andet fusionsprotein omfattende et AGT-polypeptid, der har en 06-alkylguanin-DNA-alkyltransferaseaktivitet, og en anden epitop, der genken- D des af et andet target-antistof, men ikke af det første target-antistof, hvor AGT-substratet yderligere er kovalent koblet til den anden faste bærer, til detektering af mindst to target-antistoffer i en biologisk prøve fra et individ, fortrinsvis til diagnosticering af mindst to target-sygdomme hos et individ, hvor target-sygdommen er en virusinfektion forårsaget af en Papillomavirus 5 eller en RNA-virus fra familien Flaviviridae (Dengue-, gul feber-, West Nile-, japansk hjernebetændelse-, centraleuropæisk hjernebetændelse-, hepatitis C-vira), Togaviridae (Chikungunya-, Ross River-, Mayaro-, vestlig he-steencephalitis-, østlig hesteencephalitis-, venezuelansk hesteencephalitis-vira), Bunyaviridae (Krim-Congo hæmoragisk feber-, Rift Valley-feber-, Sch-0 mallenberg-vira), Caliciviridae (hepatitis E-virus), Arenaviridae (Lassa) eller Filoviridae (Ebola, Marburg), en bakteriel infektion forårsaget af Leptospirosa Interrogans eller en infektion forårsaget af Plasmodium falciparum.
  9. 9. In v/fro-fremgangsmåde til diagnosticering af mindst én target-sygdom hos 5 et individ, hvilken target-sygdom vides at inducere syntese af mindst to tar get-antistoffer hos individet, omfattende at udføre assay-fremgangsmåden ifølge et hvilket som helst af kravene 1 til 7, hvor individet er diagnosticeret som lidende af mindst én target-sygdom, hvis mængden af mindst to target-antistoffer er højere end kontrolværdier. D
  10. 10. In wfro-diagnosticeringsfremgangsmåde ifølge krav 9, hvor fremgangsmåden anvendes til at diagnosticere mindst 5, mere fortrinsvis mindst 15 og endnu mere foretrukket mindst 50 virusinfektioner hos individet.
  11. 11. Multiplex-immunscreeningsassay-fremgangsmåde under anvendelse af mindst 2, 25, 50, 96 faste bærere som defineret i krav 1, hvor hver af de faste *+ bærere udsender en forskellig og skelnelig bølgelængde efter excitation.
  12. 12. Multiplex-immunscreeningsassay-fremgangsmåde ifølge krav 11, omfattende: 5 a) at bringe en eller flere biologiske prøver i kontakt med mindst 2, 25, 50, 96 faste bærere som defineret i krav 1, hvor hver af de faste bærere udsender en forskellig og skelnelig bølgelængde efter excitation, og b) at detektere forekomst eller fravær af target-antistoffer, hvilke target-antistoffer fortrinsvis er mærket med et detekterbart mærke.
DK12798308.8T 2011-12-09 2012-12-10 Multiplex-immunscreeningsassay DK2788478T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2011/072387 WO2012076715A1 (en) 2010-12-09 2011-12-09 Mgmt-based method for obtaining high yield of recombinant protein expression
US201261642924P 2012-05-04 2012-05-04
PCT/EP2012/074986 WO2013083847A2 (en) 2011-12-09 2012-12-10 Multiplex immuno screening assay

Publications (1)

Publication Number Publication Date
DK2788478T3 true DK2788478T3 (da) 2017-10-09

Family

ID=49514226

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12798308.8T DK2788478T3 (da) 2011-12-09 2012-12-10 Multiplex-immunscreeningsassay

Country Status (15)

Country Link
US (5) US9638692B2 (da)
EP (2) EP2788478B1 (da)
JP (2) JP6215223B2 (da)
KR (2) KR102007061B1 (da)
CN (2) CN104114697A (da)
AU (2) AU2012350229B2 (da)
BR (2) BR112014013745B1 (da)
CA (2) CA2857998C (da)
DK (1) DK2788478T3 (da)
ES (1) ES2648899T3 (da)
MX (2) MX349562B (da)
NO (1) NO2788478T3 (da)
NZ (1) NZ701380A (da)
SG (2) SG11201403010TA (da)
WO (2) WO2013083847A2 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013014457A8 (pt) * 2010-12-09 2017-12-19 Pasteur Institut usos da enzima 6-metilguanina-dna-metiltrasferase (mgmt, ec 2.1.1.63) para aumentar a produção de proteína heteróloga, bem como vetor de expressão, células recombinantes e polipeptídeo de fusão compreendendo sinal de secreção peptídica e proteína snap
KR102007061B1 (ko) 2011-12-09 2019-08-02 앵스띠뛰 파스퇴르 다중 면역 스크리닝 분석
GB201210226D0 (en) * 2012-06-11 2012-07-25 Univ St Andrews Vaccine
WO2014045254A2 (en) 2012-09-23 2014-03-27 Erasmus University Medical Center Rotterdam Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
EP2901157B1 (en) * 2012-09-27 2021-12-15 IDEXX Laboratories, Inc. Method of detection of schmallenberg virus (sbv) and kit
US9556419B2 (en) * 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
WO2014154336A1 (en) * 2013-03-26 2014-10-02 Iffmedic Gmbh Microtiter plate-based microarray
CN103472221A (zh) * 2013-08-12 2013-12-25 南昌大学 荧光微球标记沙丁胺醇多克隆抗体的方法
IL305392A (en) 2013-11-29 2023-10-01 Inovio Pharmaceuticals Inc MERS-COV vaccine
WO2015134938A1 (en) 2014-03-07 2015-09-11 The Regents Of The University Of California Devices for integrating analyte extraction, concentration and detection
MX2017006287A (es) 2014-11-27 2017-08-14 Kimberly Clark Co Dispositivos y metodos para detectar norovirus en superficies.
CN104844710B (zh) * 2015-04-13 2018-02-02 西北大学 定向固定化pega复合型树酯的制备方法及应用
CN108139402B (zh) 2015-09-04 2022-10-18 加利福尼亚大学董事会 用于临床应用的分析物收集、提取、浓缩和检测的方法和装置
CN105368873A (zh) * 2015-11-23 2016-03-02 艾军 一种表达施马伦贝格病毒重组n基因杆状病毒的制备、鉴定方法以及应用
EP3184119A1 (en) * 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
CN105548540A (zh) * 2015-12-29 2016-05-04 中国医学科学院医学生物学研究所 一种i-iv型登革热病毒的通用检测试剂盒
WO2017147458A1 (en) * 2016-02-25 2017-08-31 The Trustees Of The University Of Pennsylvania Novel vaccines against zika virus
EP3229024A1 (de) * 2016-04-08 2017-10-11 Viramed Biotech AG Zika virus diagnostik
US11828755B2 (en) 2016-06-09 2023-11-28 The Regents Of The University Of California Biomarker concentration and signal amplification for use in paper-based immunoassays and a single platform for extracting, concentrating, and amplifying DNA
WO2018039139A1 (en) * 2016-08-22 2018-03-01 The Regents Of The University Of California Hydrogel platform for aqueous two-phase concentration of a target to enhance its detection
US10012645B2 (en) * 2016-08-24 2018-07-03 The Florida International University Board Of Trustees Rapid zika virus detection using nano-enabled electrochemical sensing system
US11651866B2 (en) * 2016-10-17 2023-05-16 Reliant Immune Diagnostics, Inc. System and method for real-time insurance quote in response to a self-diagnostic test
US11107585B2 (en) 2016-10-17 2021-08-31 Reliant Immune Diagnostics, Inc System and method for a digital consumer medical wallet and storehouse
US11579145B2 (en) 2016-10-17 2023-02-14 Reliant Immune Diagnostics, Inc. System and method for image analysis of medical test results
US9857372B1 (en) 2016-10-17 2018-01-02 Reliant Immune Diagnostics, LLC Arbovirus indicative birth defect risk test
US11693002B2 (en) 2016-10-17 2023-07-04 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results using visual indicia to determine medical test function type
US11802868B2 (en) 2016-10-17 2023-10-31 Reliant Immune Diagnostics, Inc. System and method for variable function mobile application for providing medical test results
US10902951B2 (en) 2016-10-17 2021-01-26 Reliant Immune Diagnostics, Inc. System and method for machine learning application for providing medical test results using visual indicia
EP3361256A1 (en) * 2017-02-08 2018-08-15 Fundación para la Investigación Médica Aplicada In vitro method for the diagnosis of lung cancer
CN108503697B (zh) * 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 一种果蝇细胞表达的寨卡病毒亚单位疫苗
CN107102144A (zh) * 2017-03-16 2017-08-29 深圳市梓健生物科技有限公司 快速检测寨卡病毒ns1蛋白的荧光定量免疫层析试纸条及其制作方法
WO2018183211A1 (en) 2017-03-27 2018-10-04 The Regents Of The University Of California Semi-quantitative lateral-flow immunoassay for the detection of csf leaks
CN107287347B (zh) * 2017-05-09 2020-12-25 广州机场出入境检验检疫局综合技术服务中心 戊型肝炎病毒实时荧光逆转录pcr检测引物、探针、检测试剂盒和检测方法
RU2661085C1 (ru) * 2017-06-01 2018-07-11 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Рекомбинантные белки, содержащие антигенные эпитопы белков Core, Small Envelope, NS2A и preM вируса Зика, и комплексный антиген, содержащий указанные белки и используемый в качестве компонента иммуноферментной тест-системы для выявления антител классов G и M к вирусу Зика
WO2019039557A1 (ja) * 2017-08-24 2019-02-28 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
WO2019055971A2 (en) * 2017-09-18 2019-03-21 Carrera Bioscience Inc. MULTIPLEX ENTERIC MEASUREMENTS AND METHODS OF USE
JP6939535B2 (ja) * 2017-12-27 2021-09-22 トヨタ自動車株式会社 車両用撮影装置及び加熱装置
KR102198342B1 (ko) * 2019-05-22 2021-01-04 연세대학교 산학협력단 항체 선별 방법 및 이를 이용한 항체 선별 시스템
WO2021067181A1 (en) * 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
MX2022011671A (es) * 2020-03-20 2023-01-24 BioNTech SE Vacunas contra el coronavirus y metodos de uso.
WO2021194540A1 (en) * 2020-03-23 2021-09-30 Baseline Viral Diagnostics, Inc. Methods, systems, and a kit for detection, diagnosis, monitoring and treatment of covid-19
EP4143347A1 (en) * 2020-04-28 2023-03-08 Aviana Molecular Technologies, LLC Compositions and surface acoustic wave based methods for identifying infectious disease
US20210349105A1 (en) * 2020-05-07 2021-11-11 Bio-Rad Laboratories, Inc. Sars-cov-2 immunoassay and materials therefor
WO2021236050A1 (en) 2020-05-18 2021-11-25 Baseline Global, Inc. Assay device, system, method, and kit
JP2023526204A (ja) * 2020-05-19 2023-06-21 アディテックス，インコーポレイテッド 複数の免疫グロブリンアイソタイプのためのダブルマルチプレックスアッセイ
WO2021247398A1 (en) * 2020-05-30 2021-12-09 Pangolin Llc Systems and methods to detect pathogens
CA3188581A1 (en) * 2020-07-02 2022-01-06 The Regents Of The University Of California Persistent memory t-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways
WO2022020234A2 (en) * 2020-07-20 2022-01-27 Bio-Rad Laboratories, Inc. Immunoassay for sars-cov-2 neutralizing antibodies and materials therefor
US20220050105A1 (en) * 2020-08-12 2022-02-17 Boston Molecules, Inc. Method and apparatus for detecting viruses in biological samples
WO2022036337A1 (en) * 2020-08-13 2022-02-17 Diaclone Llc Compositions and methods for recombinant polypeptide mimicking sars-cov-2 nucleocapsid protein (np)
CN112760420B (zh) * 2021-02-05 2023-05-26 中国科学院长春应用化学研究所 一种用于检测新冠病毒SARS-CoV-2的引物、探针和试剂盒
WO2022241256A1 (en) * 2021-05-13 2022-11-17 Serimmune Inc. Serum antibody profiling for leptospirosis
US20230176072A1 (en) * 2021-12-02 2023-06-08 Zymeron Corporation Novel Immunoassay Platform for the Serological Discrimination of Closely Related Viruses

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480764B1 (fr) 1980-04-18 1985-10-04 Rhone Poulenc Spec Chim Latex de polymeres magnetiques et procede de preparation
NO155316C (no) 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
GB2125047B (en) 1982-08-09 1986-02-19 Ciba Geigy Ag Yeast hybrid vectors and their use for the production of polypeptides
EP0118551A1 (en) 1982-09-15 1984-09-19 Collaborative Research Inc. Production of interferon in yeast by use of invertase promoter
EP0243465A1 (en) 1985-10-25 1987-11-04 Vivian L. Mackay Method of using bar1 for secreting foreign proteins
FR2645160B1 (da) 1989-03-31 1992-10-02 Rhone Poulenc Chimie
US5879926A (en) 1989-03-31 1999-03-09 Transgene S.A. Yeast strains for the production of mature heterologous proteins, especially hirudin
JP2979414B2 (ja) 1989-09-29 1999-11-15 富士レビオ株式会社 磁性粒子およびそれを用いた免疫測定法
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9224888D0 (en) * 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
DK82893D0 (da) 1993-07-08 1993-07-08 Novo Nordisk As Peptid
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US5736330A (en) 1995-10-11 1998-04-07 Luminex Corporation Method and compositions for flow cytometric determination of DNA sequences
EP0852004B1 (en) 1995-10-11 2011-01-19 Luminex Corporation Multiplexed analysis of clinical specimens
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6449562B1 (en) 1996-10-10 2002-09-10 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and method
AU1080999A (en) 1997-10-14 1999-05-03 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
KR100593712B1 (ko) 1998-01-22 2006-06-30 루미넥스 코포레이션 다수의 형광 시그널을 갖는 마이크로입자
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US6649414B1 (en) * 1999-08-17 2003-11-18 Luminex Corporation Microparticles with multiple fluorescent signals and methods of using same
WO2001013119A1 (en) 1999-08-17 2001-02-22 Luminex Corporation Encapsulation of fluorescent particles
ES2447115T3 (es) 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
US9709559B2 (en) * 2000-06-21 2017-07-18 Bioarray Solutions, Ltd. Multianalyte molecular analysis using application-specific random particle arrays
US6689615B1 (en) * 2000-10-04 2004-02-10 James Murto Methods and devices for processing blood samples
DE60212642T2 (de) * 2001-04-10 2007-06-14 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Verfahren zur verwendung von o6-alkylguanin-dna-alkyltransferasen
ATE470859T1 (de) * 2001-09-06 2010-06-15 Straus Holdings Inc Schneller und empfindlicher nachweis von molekülen
US6682507B2 (en) 2002-02-20 2004-01-27 Doug's Kangaroo Pouch, Llc User wearable device having sterile environment for connecting peritoneal dialysis tubes
WO2003093511A1 (en) * 2002-04-30 2003-11-13 Merck & Co., Inc. Human papillomavirus multiplexed assay
KR20050049513A (ko) * 2002-10-03 2005-05-25 에콜 폴리테크니크 페데랄레 드 로잔 Ｏ6-알킬구아닌-ｄｎａ 알킬트랜스퍼라제를 사용한 단백질라벨링
US7799524B2 (en) 2002-10-03 2010-09-21 Ecole Polytechnique Ferdeale de Lausanne Substrates for O6-alkylguanina-DNA alkyltransferase
WO2004036220A1 (en) 2002-10-18 2004-04-29 Rescom Gmbh Diagnosis of glaucoma by complex autoantibody repertoires in body fluids
AU2003296921A1 (en) * 2002-10-31 2004-05-25 Health Research, Inc. Diagnostic test for west nile virus
US8163479B2 (en) 2004-03-02 2012-04-24 Ecole Polytechnique Federale De Lausanne Specific substrates for O6-alkylguanine-DNA alkyltransferase
CA2495138C (en) * 2005-01-20 2012-10-23 Alison Jane Basile Multiplexed analysis for determining a serodiagnosis of viral infection
AU2006231470B2 (en) * 2005-04-05 2011-12-01 Allergan, Inc. Lipophilic dye-based FRET assays for Clostridial toxin activity
AU2006340711C1 (en) * 2005-04-05 2013-02-07 Allergan, Inc. Clostridial toxin activity assays
EP1874738B1 (en) 2005-04-27 2016-06-29 Covalys Biosciences AG Pyrimidines reacting with o6-alkylguanine-dna alkyltransferase
EP1882688A1 (en) * 2006-07-25 2008-01-30 EPFL Ecole Polytechnique Fédérale de Lausanne Labelling of fusion proteins with synthetic probes
AU2009251881B2 (en) * 2008-03-31 2015-03-26 Pacific Biosciences Of California, Inc Single molecule loading methods and compositions
FR2936245B1 (fr) * 2008-09-23 2012-07-06 Cis Bio Int Nouveaux substrats d'o6-alkylguanine-adn alkyltransferase et ses mutants.
AU2009342630B2 (en) 2009-03-18 2015-09-03 Nestec S.A. Addressable antibody arrays and methods of use
JP2013527752A (ja) * 2010-03-23 2013-07-04 ジンジェン バイオ カンパニー リミテッド 融合ポリペプチドｈｐｖ抗原を用いたｈｐｖ抗体スクリーニング方法
BR112013014457A8 (pt) 2010-12-09 2017-12-19 Pasteur Institut usos da enzima 6-metilguanina-dna-metiltrasferase (mgmt, ec 2.1.1.63) para aumentar a produção de proteína heteróloga, bem como vetor de expressão, células recombinantes e polipeptídeo de fusão compreendendo sinal de secreção peptídica e proteína snap
KR102007061B1 (ko) 2011-12-09 2019-08-02 앵스띠뛰 파스퇴르 다중 면역 스크리닝 분석

Also Published As

Publication number Publication date
SG11201403010TA (en) 2014-07-30
US10352930B2 (en) 2019-07-16
BR112014027465A2 (pt) 2017-06-27
CA2872127A1 (en) 2013-11-07
BR112014027465A8 (pt) 2021-06-29
WO2013083847A3 (en) 2013-08-01
US20170336412A1 (en) 2017-11-23
US10209248B2 (en) 2019-02-19
US9638692B2 (en) 2017-05-02
ES2648899T3 (es) 2018-01-08
NZ701380A (en) 2016-03-31
KR102049623B1 (ko) 2019-11-28
US10119967B2 (en) 2018-11-06
MX349562B (es) 2017-08-02
MX2014013417A (es) 2014-11-26
WO2013164476A1 (en) 2013-11-07
MX2014006870A (es) 2014-11-25
WO2013083847A2 (en) 2013-06-13
EP2788478B1 (en) 2017-08-23
MX357087B (es) 2018-06-25
BR112014013745B1 (pt) 2022-06-14
JP2015500989A (ja) 2015-01-08
NO2788478T3 (da) 2018-01-20
EP2788478A2 (en) 2014-10-15
JP6351571B2 (ja) 2018-07-04
CA2857998A1 (en) 2013-06-13
JP2015517649A (ja) 2015-06-22
KR102007061B1 (ko) 2019-08-02
CN104704117A (zh) 2015-06-10
CN104704117B (zh) 2018-08-03
JP6215223B2 (ja) 2017-10-18
US20150099656A1 (en) 2015-04-09
CN104114697A (zh) 2014-10-22
KR20140113937A (ko) 2014-09-25
BR112014027465B1 (pt) 2022-07-12
EP2844748A1 (en) 2015-03-11
US20180038852A1 (en) 2018-02-08
AU2012350229B2 (en) 2018-03-22
CA2857998C (en) 2021-01-19
AU2013255744A1 (en) 2014-11-13
SG11201407167RA (en) 2014-11-27
KR20150016941A (ko) 2015-02-13
US20170276672A1 (en) 2017-09-28
US20140274762A1 (en) 2014-09-18
AU2012350229A1 (en) 2014-07-17
BR112014013745A2 (pt) 2017-12-12
US10197562B2 (en) 2019-02-05
EP2844748B1 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
DK2788478T3 (da) Multiplex-immunscreeningsassay
KR100886312B1 (ko) 단백질-단백질의 상호작용을 분석하는 방법
KR102606929B1 (ko) 동족 항원과 t-세포 수용체 상호작용의 발견 및 특징규명을 위한 조작된 2-부분 세포 디바이스
CN110656090B (zh) 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
DK2925866T3 (da) Cirkulært rna til inhibering af mikro-rna
CN110023500A (zh) 作为选择标记的减毒谷氨酰胺合成酶
CN101208425A (zh) 产生复制缺陷型腺病毒的细胞系
KR20210108423A (ko) 아데노 관련 바이러스 (aav) 생산자 세포주 및 관련 방법
JP2003534775A (ja) タンパク質を不安定化する方法とその使用
AU2024200154A1 (en) An engineered multi-component system for identification and characterisation of T-cell receptors, T-cell antigens and their functional interaction
AU2016378480A1 (en) Endothelium-specific nucleic acid regulatory elements and methods and use thereof
CN108949825A (zh) 一种靶向her2的car-t细胞的制备方法及应用
KR102614328B1 (ko) T-세포 수용체 합성 및 tcr-제시 세포에 대한 안정적인 게놈 통합을 위한 2-부분 디바이스
JP2023025182A (ja) Ｔ細胞レセプター及びｔ細胞抗原の同定及び特徴決定のための遺伝子操作された多成分システム
KR20230056630A (ko) 신규의 omni-59, 61, 67, 76, 79, 80, 81 및 82 crispr 뉴클레아제
KR20230019063A (ko) C9orf72 연관 질환의 치료를 위한 삼중 기능 아데노-연관 바이러스 (aav) 벡터
KR20220016485A (ko) 미엘린 단백질 제로 프로모터를 갖는 aav 벡터, 및 샤르코-마리-투스 질환과 같은 슈반 세포-관련 질환을 치료하기 위한 이의 용도
CN112877292A (zh) 产生人抗体的细胞
CN110343713A (zh) 一种基于人源tlr4基因的多功能双荧光素酶报告基因载体及其构建方法与应用
KR20240021906A (ko) 발현 벡터, 박테리아 서열-무함유 벡터, 및 이를 제조하고 사용하는 방법
CN110777147A (zh) 一种ikzf3基因沉默的t细胞及其应用
CN114231513B (zh) 一种可抑制蛋白酶体psmb5亚基活性的短肽及其在抗立克次体感染中的应用
CN112063655A (zh) 一种端粒基因治疗产品和哺乳动物广泛性启动子的用途
CN114134141B (zh) 一种引入非天然氨基酸的嵌合体苯丙氨酸翻译系统及其构建方法
CN114805537A (zh) 一种表达犬白介素6的重组质粒、稳定表达犬白介素6蛋白的细胞株及其制备方法和应用